Properties (58)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
monoclonal antibody
|
| gptkbp:activeDuring |
belantamab_mafodotin
|
| gptkbp:administrativeDivision |
administered by healthcare professionals
once every 3 weeks monitor for infusion reactions during administration |
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:canCreate |
primarily through the liver
|
| gptkbp:clinicalTrials |
Phase 2
relapsed or refractory multiple myeloma conducted in multiple countries included in treatment guidelines for multiple myeloma for patients with specific genetic markers showed overall response rate of 31% in trials studied in multiple phases of clinical trials improves progression-free survival in some patients |
| gptkbp:community_service |
available for eligible patients
overall survival and response rate |
| gptkbp:contraindication |
hypersensitivity to the active substance
may cause vision changes |
| gptkbp:customerFeedback |
generally positive regarding efficacy
|
| gptkbp:dosageForm |
lyophilized powder for solution
based on patient weight |
| gptkbp:drugInterdiction |
half-life approximately 3 weeks
may interact with other immunosuppressants ongoing monitoring for long-term effects targets_and_binds_to_BCMA_on_myeloma_cells |
| gptkbp:firstAppearance |
August 2020
|
| gptkbp:hasPopulation |
adults
|
| gptkbp:hasVariants |
can be used with other therapies
|
| gptkbp:healthcare |
important for treatment efficacy
patients should be informed about potential side effects providers should be trained on administration and monitoring. |
| gptkbp:historicalEvent |
developed_by_GSK_and_partnered_with_other_companies
|
| https://www.w3.org/2000/01/rdf-schema#label |
Blenrep
|
| gptkbp:impact |
depends on patient response and tolerance
|
| gptkbp:insuranceAccepted |
may vary by plan
|
| gptkbp:is_monitored_by |
ocular examinations
|
| gptkbp:manufacturer |
gptkb:GlaxoSmithKline
|
| gptkbp:marketSegment |
available_in_the_United_States
|
| gptkbp:offers |
considered high-cost therapy
|
| gptkbp:regulatoryCompliance |
submitted for approval in multiple countries
orphan_drug_designation_for_multiple_myeloma |
| gptkbp:researchFocus |
ongoing studies for combination therapies
|
| gptkbp:researchInterest |
numerous studies published in medical journals
collaborated with academic institutions for studies |
| gptkbp:route |
intravenous
|
| gptkbp:safetyFeatures |
risk of serious infections
requires monitoring for ocular toxicity |
| gptkbp:sideEffect |
anemia
thrombocytopenia infusion-related reactions neutropenia corneal toxicity |
| gptkbp:storage |
store at 2°C to 8°C
|
| gptkbp:supplyChain |
distributed through specialty pharmacies
|
| gptkbp:targets |
BCMA
|
| gptkbp:triggerType |
antibody-drug conjugate
|
| gptkbp:usedFor |
treatment of multiple myeloma
|